NCT00028327View on ClinicalTrials.gov

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

Not specified

Primary Completion Date

July 31, 2004

Conditions
HIV Infections
Interventions
DRUG

Lamivudine/Zidovudine

DRUG

Nelfinavir mesylate

DRUG

Efavirenz

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (9)

10003

Beth Israel Med Ctr, New York

21287

Johns Hopkins Hosp, Baltimore

27710

Duke Univ Med Ctr, Durham

63108

Washington Univ School of Medicine, St Louis

92103

Univ of California, San Diego, San Diego

94110

Univ of California San Francisco, San Francisco

98104

Univ of Washington, Seattle

331361013

Univ of Miami School of Medicine, Miami

90033-1079

Univ of Southern California, Los Angeles

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00028327 - Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care | Biotech Hunter | Biotech Hunter